Download PDFPDF
Original research
Clinical efficacy and tolerability of 1.5 g/day oral amoxicillin therapy without probenecid for the treatment of syphilis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Concern regarding the external validity and feasibility of low dose long term amoxicillin therapy against syphilis
    • Takuma Matsuda, physician Kita Harima Medical Center
    • Other Contributors:
      • Rie Tominaga, physician
      • Kentaro Iwata, physician

    To the editor.

    We read with interest an article by Ikeuchi et al.1 We agree with their conclusion that the relatively low dose of amoxicillin could lead to the cure of syphilis. However, we would like to raise concern that the findings might not be generalized to different populations. The majority of the patients had concurrent HIV infection, and the study setting is well known prestigious center for HIV care in Japan, with decades of HIV care in Tokyo, suggesting that the patients who participated in the study are likely to be adherent to the medications prescribed, because they are instructed thoroughly in taking antiretroviral therapy. In addition, those who did not have HIV infection in the study did not have a previous history of syphilis, and they might also be likely to be adherent to the regimen compared with those who had repeated STDs. As pointed out in the study, the recommended duration of amoxicillin therapy by Japanese STD guideline is very long (4-8 weeks), and we are not sure whether patients with syphilis in general can be adherent to this regimen. Therefore, we consider that the findings by Ikeuchi et al. may not be generalizable, particularly for those who are not very aware of the importance of adherence to the medication, or those who take the risk of STDs lightly (and have repeated STDs). Future studies with different settings and populations might clarify our concerns.

    1. Ikeuchi K, Fukushima K, Tanaka M, Yajima K, Im...

    Show More
    Conflict of Interest:
    None declared.